Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.
1. A therapeutic construct comprising:
a mesoporous silica nanoparticle comprising (MSNP) platform loaded with: a small molecule Polo-like Kinase (PLK1) inhibitor or a PLK1 siRNA; and
a Programmed Death-Ligand 1 (PD-L1) antibody conjugated onto the MSNP platform: wherein the small molecule PLK1 inhibitor makes up 0.01% to 5% by weight of the therapeutic construct.
2. The therapeutic construct of claim 1 , wherein the small molecule PLK1 inhibitor comprises at least one of GSK461364, BI2536, Tak960, NMS-P937, or volasertib.
3. The therapeutic construct of claim 1 , wherein the small molecule PLK1 inhibitor comprises volasertib.
4. The therapeutic construct of claim 1 , wherein the nanoparticle is coated with cross-linked polyethylenimine (PEI) and polyethylene glycol.
5. The therapeutic construct of claim 1 , wherein the PLK1 siRNA makes up 0.1% to 20% by weight of the therapeutic construct.
6. The therapeutic construct of claim 1 , wherein the PD-L1 antibody makes up 0.1% to 20% by weight of the therapeutic construct.
7. The therapeutic construct of claim 1 , wherein the nanoparticle has a mean particle size of about 30-80 nm.
8. The therapeutic construct of claim 1 , having a hydrodynamic size of about 80-200 nm.
9. The therapeutic construct of claim 1 , further comprising an adjuvant.
10. The therapeutic construct of claim 9 , wherein the adjuvant is a CpG oligonucleotide.
11. The therapeutic construct of claim 10 , wherein the adjuvant is CpG ODN 7909.
12. A composition comprising:
the therapeutic construct of claim 1 ; and
a pharmaceutically acceptable carrier, excipient, or diluent.
13. A method of treating a subject diagnosed as having a hyperproliferative disease or condition, comprising administering to the subject an effective amount of the composition of claim 12 .
14. The method of claim 13 , wherein the subject is a mammal.
15. The method of claim 14 , wherein the mammal is a human.
16. The method of claim 15 , wherein the hyperproliferative disease comprises one or more of cancer, precancer, or cancer metastasis.
17. The method of claim 16 , wherein the hyperproliferative disease comprises one or more of melanoma, lung cancer, breast cancer, pancreatic cancer, brain cancer, prostate cancer, head and neck cancer, kidney cancer, colorectal cancer, lymphoma, colon cancer, or liver cancer.
18. The method of claim 17 , wherein administering comprises one or more of:
injection to or at a tumor in the subject;
infusion locally to or at a tumor in the subject;
systemic injection in the subject;
systemic infusion in the subject;
oral administration to the subject; or
topical application to the subject.
19. The method of claim 17 , wherein administering comprises:
intravenous injection; or
intratumoral injection.
20. The method of claim 17 , further comprising administering to the subject an anti-cancer therapy comprising an anti-cancer agent or any form of radiation therapy.
21. A therapeutic construct comprising:
a mesoporous silica nanoparticle (MSNP) platform comprising 0.01% to 5% mitotic kinase inhibitor, by weight of the therapeutic construct; and
an antibody against PD-L1 conjugated onto the MSNP platform.
22. The therapeutic construct of claim 12 , wherein the mitotic kinase inhibitor comprises at least one of volasertib, alisertib, or AZD7762.
23. The therapeutic construct of claim 12 , wherein the nanoparticle is coated with cross-linked polyethylenimine and polyethylene glycol.
24. The therapeutic construct of claim 21 , wherein the PD-L1 antibody makes up 0.1% to 20% by weight of the therapeutic construct.
25. The therapeutic construct of claim 21 , wherein the nanoparticle has a mean particle size of about 30-80 nm.
26. The therapeutic construct of claim 12 , having a hydrodynamic size of about 80-200 nm.
27. The therapeutic construct of claim 21 , further comprising an adjuvant.
28. The therapeutic construct of claim 27 , wherein the adjuvant is a CpG oligonucleotide.
29. The therapeutic construct of claim 28 , wherein the adjuvant is CpG ODN 7909.
30. A composition comprising:
the therapeutic construct of claim 21 ; and
a pharmaceutically acceptable carrier, excipient, or diluent.
31. A method of treating a subject diagnosed as having a hyperproliferative disease or condition, comprising administering to the subject an effective amount of the composition of claim 30 .
32. The method of claim 31 , wherein the subject is a mammal.
33. The method of claim 32 , wherein the mammal is a human.
34. The method of claim 33 , wherein the hyperproliferative disease comprises one or more of cancer, precancer, or cancer metastasis.
35. The method of claim 34 , wherein the hyperproliferative disease comprises one or more of melanoma, lung cancer, breast cancer, pancreatic cancer, brain cancer, prostate cancer, head and neck cancer, kidney cancer, colorectal cancer, lymphoma, colon cancer, or liver cancer.
36. The method of claim 35 , wherein administering comprises one or more of:
injection to or at a tumor in the subject;
infusion locally to or at a tumor in the subject;
systemic injection in the subject;
systemic infusion in the subject;
oral administration to the subject; or
topical application to the subject.
37. The method of claim 35 , wherein administering comprises:
intravenous injection; or
intratumoral injection.
38. The method of claim 35 , further comprising administering to the subject an anti- cancer therapy comprising an anti-cancer agent or any form of radiation therapy.
39. A therapeutic construct comprising:
a mesoporous silica nanoparticle (MSNP) platform comprising PLK1 siRNA; and
an antibody against PD-L1 conjugated onto the MSNP platform.
40. The therapeutic construct of claim 39 , wherein the MSNP platform comprises 0.1% to 20% PLK1 siRNA, by weight of the therapeutic construct.
41. The therapeutic construct of claim 39 , wherein the MSNP platform comprises 2-4% PLK1 siRNA, by weight of the therapeutic construct.
42. The therapeutic construct of claim 39 , wherein the nanoparticle is coated with cross-linked polyethylenimine and polyethylene glycol.
43. A composition comprising:
the therapeutic construct of claim 39 ; and
a pharmaceutically acceptable carrier, excipient, or diluent.
44. A method of treating a subject diagnosed as having a hyperproliferative disease or condition, comprising administering to the subject an effective amount of the composition of claim 43 .
45. The method of claim 44 , wherein the subject is a mammal.
46. The method of claim 45 , wherein the mammal is a human.
47. The method of claim 46 , wherein the hyperproliferative disease comprises one or more of cancer, precancer, or cancer metastasis.
48. The method of claim 47 , wherein the hyperproliferative disease comprises one or more of melanoma, lung cancer, breast cancer, pancreatic cancer, brain cancer, prostate cancer, head and neck cancer, kidney cancer, colorectal cancer, lymphoma, colon cancer, or liver cancer.
49. The method of claim 48 , wherein administering comprises one or more of:
injection to or at a tumor in the subject;
infusion locally to or at a tumor in the subject;
systemic injection in the subject;
systemic infusion in the subject;
oral administration to the subject; or
topical application to the subject.
50. The method of claim 49 , wherein administering comprises:
intravenous injection; or
intratumoral injection.
51. The method of claim 50 , further comprising administering to the subject an anti-cancer therapy comprising an anti-cancer agent or any form of radiation therapy.